Singh Kavita, Chandra Sekaran Ambalam M, Bhaumik Soumyadeep, Aisola Malini, Chattopadhyay Kaushik, Gamage Anuji U, de Silva Padmal, Selvaraj Sakthivel, Roy Ambuj, Prabhakaran Dorairaj, Tandon Nikhil
All India Institute of Medical Sciences, New Delhi, India.
Centre for Chronic Disease Control, Gurgaon, Haryana, India.
BMJ Open. 2015 Mar 10;5(3):e007205. doi: 10.1136/bmjopen-2014-007205.
While a number of strategies are being implemented to control cardiovascular diseases (CVDs) and type 2 diabetes mellitus (T2DM), the cost-effectiveness of these in the South Asian context has not been systematically evaluated. We aim to systematically review the economic (cost-effectiveness) evidence available on the individual-, group- and population-level interventions for control of CVD and T2DM in South Asia.
This review will consider all relevant economic evaluations, either conducted alongside randomised controlled trials or based on decision modelling estimates. These studies must include participants at risk of developing CVD/T2DM or with established disease in one or more of the South Asian countries (India, Bangladesh, Pakistan, Sri Lanka, Nepal, Maldives, Bhutan and Afghanistan). We will identify relevant papers by systematically searching all major databases and registries. Selected articles will be screened by two independent researchers. Methodological quality of the studies will be assessed using a modified Drummond and a Phillips checklist. Cochrane guidelines will be followed for bias assessment in the effectiveness studies.
Results will be presented in line with the PRISMA (Preferred Reporting Items for Systematic review and Meta-analysis) checklist, and overall quality of evidence will be presented as per the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) approach.
The study has received ethics approval from the All India Institute of Medical Sciences, New Delhi, India. The results of this review will provide policy-relevant recommendations for the uptake of cost-effectiveness evidence in prioritising decisions on essential chronic disease care packages for South Asia.
PROSPERO CRD42013006479.
虽然正在实施多种策略来控制心血管疾病（CVD）和2型糖尿病（T2DM），但这些策略在南亚背景下的成本效益尚未得到系统评估。我们旨在系统回顾南亚地区针对控制CVD和T2DM的个体、群体和人群层面干预措施的经济（成本效益）证据。
本综述将考虑所有相关的经济评估，这些评估要么与随机对照试验同时进行，要么基于决策模型估计。这些研究必须纳入一个或多个南亚国家（印度、孟加拉国、巴基斯坦、斯里兰卡、尼泊尔、马尔代夫、不丹和阿富汗）中有患CVD/T2DM风险或已确诊疾病的参与者。我们将通过系统检索所有主要数据库和登记处来识别相关论文。选定的文章将由两名独立研究人员进行筛选。将使用改良的德拉蒙德和菲利普斯清单评估研究的方法学质量。在有效性研究中，将遵循Cochrane指南进行偏倚评估。
结果将按照PRISMA（系统评价和Meta分析的首选报告项目）清单呈现，证据的总体质量将按照GRADE（推荐分级、评估、制定和评价）方法呈现。
该研究已获得印度新德里全印度医学科学研究所的伦理批准。本综述的结果将为在南亚基本慢性病护理包优先决策中采用成本效益证据提供与政策相关的建议。
PROSPERO CRD42013006479。
